MedTrace Logo

Mirtazapine Reduces ICD Shocks in ICD Patients With Depression and Anxiety

NCT00960830 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-08-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate if the use of antidepressant medication in depressed patients with implantable cardioverter defibrillator reduces the number of ICD's shocks as it improves depressive affect.

Conditions

Interventions

DRUG

mirtazapine

mirtazapine 15 mg daily tablets

DRUG

mirtazapine

15 mg daily

Sponsors & Collaborators

  • Universidad Nacional de Rosario

    lead OTHER

Principal Investigators

  • daniel jl serrani, MD · facultad de psicologia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
65 Years
Max Age
87 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-04-30
Completion
2008-11-30

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00960830 on ClinicalTrials.gov